PPT-A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose

Magnus Ohman MB on behalf of the GEMINIACS1 Investigators Committees and D isclosures Academic Executive Committee E Magnus Ohman MB Cochair C Michael Gibson MS MD Cochair Matthew T Roe MD MHS. Alexander T Cohen . On behalf of the MAGELLAN Steering Committee and Investigators. Potential conflicts. Dr AT Cohen is a medical consultant for and has received honoraria, consultancy and clinical trial funding from many pharmaceutical companies, including: . (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . G. . Turpie. Professor Emeritus of Medicine. McMaster University. Hamilton ON. Canada. Future Challenges. Disclosures for Dr A.G.G. Turpie. Research Support. None. Employee. None. Consultant and/or Honoraria. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Mortality Risks . in . Elderly Medicare Beneficiaries . Treated . with Dabigatran . or Rivaroxaban . for . Nonvalvular. Atrial Fibrillation. To compare risks of thromboembolic stroke, intracranial hemorrhage, major . Babak Moini, MD. Veterans Affairs Hospital. Noon Lecture . S. eries. Acknowledgment: . Some of the slides were borrowed from Amanda Miller Phar.D. . Case1. 68 male with . hx. of DM, CHF and prior ischemic CVA admitted for new . Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators Weitz JI et al. N Engl J Med 2017 ( In Press) Rivaroxaban or Aspirin for Extended Treatment of Venous  Thromboembolism Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators Background Community studies have shown that gastrointestinal (GI) and genitourinary (GU) bleeding may be the first sign of underlying cancer Christopher Granger, . MD. Sean Pokorney, MD. . Disclosure (Dr. Granger). Research contracts: AstraZeneca, Daiichi, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, Medtronic Foundation, The Medicines Company, and Boehringer . & safe anticoagulant prescribing. July 2020. Dr Clare Brown . Slides by Dr . Julia . Anderson. Department of Haematology. Royal Infirmary of Edinburgh. Plan for today. Where to locate the antithrombotic guidelines and protocols. VTE death. ) for . rivaroxaban. vs. . enoxaparin. : 2.7% vs. 2.7%, p for . noninferiority. = 0.0025; at 35 days: 4.4% vs. 5.7%, p = 0.02. Clinically relevant bleeding at 10 days: . 2.8. % vs. 1.2%; at . Kourosh. . Sadeghi. Tehran University of medical sciences. New Oral Anticoagulants (NOACs). Available in Iran. NOACs. Clinical Trials. RE-LY Study. 951 . clinical . centers in . 44 . countries, . Non-inferiority trial, 18,113 patients, fixed doses of dabigatran 110 mg or 150 mg twice daily — or, in an un-blinded fashion, adjusted-dose warfarin. . Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP. Professor of Pharmacy Practice and Science. University of Nebraska Medical Center College of Pharmacy. Omaha, Nebraska USA. Disclosures. Consultant for the follow entities:.